Insulin Action in Individuals With Type 2 Diabetes by Natural Fatty Acids or the Medication Pioglitazone

This study is currently recruiting participants.

Verified by Albert Einstein College of Medicine of Yeshiva University, January 2005

Sponsors and Collaborators:	Albert Einstein College of Medicine of Yeshiva University Takeda Global Research & Development Center, Inc.
Information provided by:	Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier:	NCT00179400

Purpose

Doctors are studying natural oils as potential therapies for type 2 diabetes. Animal studies have suggested promising results using EPA (found in fish oils) to improve insulin action and lower blood sugar levels.

Condition	Intervention
Type 2 Diabetes Mellitus	Drug: Pioglitazone/EPA

MedlinePlus related topics: Diabetes

Drug Information available for: Insulin Pioglitazone Pioglitazone hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Non-Randomized, Double-Blind, Placebo Control, Single Group Assignment, Pharmacodynamics Study
Official Title:	The Role of Acute Combined Peroxisome Proliferator-Activated Receptors (PPAR) Alpha and Gamma Stimulation on Insulin Action in Humans

Further study details as provided by Albert Einstein College of Medicine of Yeshiva University:

Detailed Description:

PARTICIPATION INCLUDES: Participation in the studies includes taking study capsules for up to 21 days, keeping a meal diary, and up to four overnight hospital stays. During the hospital visits, an IV will be placed in each arm, and small amounts of muscle and fat tissue will be removed (with minimal discomfort).

COMPENSATION: Compensation of $400 per study is provided (or up to $1,600 for completing all studies)

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 2 subjects with an A1c over 8.%

Exclusion Criteria:

Those with bleeding disorders including GERD, PUD, any GI bleeding; High blood pressure, and anyone with a history of Coronary Artery Disease or exertional chest pain

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00179400

Contacts

Contact: Angela Stangarone, BA

718-430-2903

astangar@aecom.yu.edu

Locations

United States, New York
Albert Einstein College of Medicine	Recruiting
Bronx, New York, United States, 10461
Contact: Meredith Hawkins, MD
Contact: Preeti Kishore, MD pkishore@aecom.yu.edu
Principal Investigator: Meredith Hawkins, MD

Sponsors and Collaborators

Albert Einstein College of Medicine of Yeshiva University

Takeda Global Research & Development Center, Inc.

Investigators

Principal Investigator:

Meredith Hawkins, MD

Albert Einstein College of Medicine of Yeshiva University

More Information

Study ID Numbers:	2000-200
Study First Received:	September 13, 2005
Last Updated:	September 13, 2005
ClinicalTrials.gov Identifier:	NCT00179400
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Metabolic Diseases
Pioglitazone
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases

Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Insulin

Additional relevant MeSH terms:

Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009